SFERA Archivio dei prodotti della Ricerca dell'Università di Ferrara

MORARI, Michele
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 9.729
EU - Europa 2.602
AS - Asia 2.364
SA - Sud America 161
AF - Africa 15
OC - Oceania 7
Continente sconosciuto - Info sul continente non disponibili 4
Totale 14.882
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 9.673
SG - Singapore 944
CN - Cina 893
UA - Ucraina 600
DE - Germania 561
IT - Italia 470
TR - Turchia 374
GB - Regno Unito 294
FI - Finlandia 281
BR - Brasile 148
SE - Svezia 148
ID - Indonesia 69
BE - Belgio 51
AT - Austria 47
CA - Canada 47
PL - Polonia 42
FR - Francia 39
NL - Olanda 19
IN - India 14
HK - Hong Kong 13
LT - Lituania 11
IR - Iran 10
RU - Federazione Russa 9
VN - Vietnam 8
CZ - Repubblica Ceca 6
AU - Australia 5
IQ - Iraq 5
MA - Marocco 5
BD - Bangladesh 4
IE - Irlanda 4
JP - Giappone 4
RO - Romania 4
ZA - Sudafrica 4
AR - Argentina 3
BG - Bulgaria 3
JO - Giordania 3
KG - Kirghizistan 3
MX - Messico 3
PK - Pakistan 3
CH - Svizzera 2
CL - Cile 2
CO - Colombia 2
DZ - Algeria 2
EC - Ecuador 2
EG - Egitto 2
EU - Europa 2
KH - Cambogia 2
LV - Lettonia 2
NO - Norvegia 2
NZ - Nuova Zelanda 2
PA - Panama 2
PH - Filippine 2
PY - Paraguay 2
UZ - Uzbekistan 2
A2 - ???statistics.table.value.countryCode.A2??? 1
AL - Albania 1
AM - Armenia 1
AZ - Azerbaigian 1
BH - Bahrain 1
BW - Botswana 1
CR - Costa Rica 1
DK - Danimarca 1
EE - Estonia 1
ES - Italia 1
HN - Honduras 1
HR - Croazia 1
JM - Giamaica 1
KE - Kenya 1
KR - Corea 1
KZ - Kazakistan 1
LK - Sri Lanka 1
NI - Nicaragua 1
NP - Nepal 1
PE - Perù 1
PS - Palestinian Territory 1
PT - Portogallo 1
QA - Qatar 1
SK - Slovacchia (Repubblica Slovacca) 1
TH - Thailandia 1
TW - Taiwan 1
VE - Venezuela 1
XK - ???statistics.table.value.countryCode.XK??? 1
Totale 14.882
Salva come PNG Salva come JPEG
Città #
Fairfield 1.266
Woodbridge 1.234
Houston 683
Ashburn 677
Jacksonville 670
Chandler 666
Santa Clara 548
Ann Arbor 517
Singapore 488
Seattle 472
Wilmington 450
Cambridge 415
Izmir 237
Beijing 229
Munich 189
Nanjing 173
Ferrara 166
Princeton 165
Helsinki 140
San Diego 114
Boardman 105
Shanghai 99
Milan 81
Jakarta 66
Bremen 65
New York 57
Shenyang 57
Brussels 50
Falls Church 48
Hebei 45
Los Angeles 45
Vienna 41
Warsaw 41
Nanchang 38
Tianjin 35
Changsha 29
Norwalk 29
Jiaxing 28
London 28
San Mateo 25
Auburn Hills 24
Washington 24
Jinan 22
Mountain View 21
Redwood City 20
Dearborn 17
Toronto 16
Zhengzhou 16
Falkenstein 15
Frankfurt am Main 14
Orange 14
Ottawa 14
Hong Kong 13
Leawood 13
Mcallen 13
Guangzhou 12
Montréal 12
São Paulo 12
Addison 11
Lappeenranta 11
Redmond 11
Tappahannock 11
Kunming 10
Verona 10
Des Moines 9
Rome 9
Bologna 8
Dong Ket 8
Indiana 8
Ningbo 8
Nuremberg 8
Taizhou 8
Augusta 7
Morciano Di Romagna 7
Ardabil 6
Brno 6
Changchun 6
Council Bluffs 6
Jyväskylä 6
Monterenzio 6
Chicago 5
Fuzhou 5
Piscataway 5
Cordignano 4
Goiânia 4
Hangzhou 4
Newark 4
Philadelphia 4
Walnut 4
Amman 3
Belo Horizonte 3
Bishkek 3
Brasília 3
Campo Grande 3
Dublin 3
Düsseldorf 3
Ferrara di Monte Baldo 3
Kilburn 3
Lanzhou 3
Marsala 3
Totale 11.055
Salva come PNG Salva come JPEG
Nome #
[Nphe(1),Arg(14),Lys(15)]nociceptin-NH2, a novel potent and selective antagonist of the nociceptin/orphanin FQ receptor 286
Acute and chronic antiparkinsonian effects of the novel nociceptin/orphanin FQ receptor antagonist NiK-21273 in comparison with SB-612111 266
Eltoprazine prevents levodopa-induced dyskinesias by reducing striatal glutamate and direct pathway activity 207
[(pF)Phe4,Arg14,Lys15]N/OFQ-NH2 (UFP-102), a highly potent and selective agonist of the nociceptin/orphanin FQ receptor 177
Pathophysiology of L-dopa-induced motor and non-motor complications in Parkinson's disease 170
Age-dependent dopamine transporter dysfunction and Serine129 phospho-α-synuclein overload in G2019S LRRK2 mice 165
D-Aspartate oxidase influences glutamatergic system homeostasis in mammalian brain 163
Anti-Parkinsonian and anti-dyskinetic profiles of two novel potent and selective nociceptin/orphanin FQ receptor agonists 162
GluN2A and GluN2B NMDA receptor subunits differentially modulate striatal output pathways and contribute to levodopa-induced abnormal involuntary movements in dyskinetic rats 153
Differential involvement of Ras-GRF1 and Ras-GRF2 in L-DOPA-induced dyskinesia 150
Amantadine attenuates levodopa-induced dyskinesia in mice and rats preventing the accompanying rise in nigral GABA levels 145
Safinamide differentially modulates in vivo glutamate and GABA release in the rat hippocampus and basal ganglia 141
AMPA receptor activation regulates the glutamate metabotropic receptor stimulated phosphatidylinositol turnover in human cerebral cortex slices 140
Loss of cortical GABA terminals in Unverricht–Lundborg disease 139
Genetic and pharmacological evidence that endogenous nociceptin/orphanin FQ contributes to dopamine cell loss in Parkinson's disease 138
5-Hydroxytryptamine-mediated effects of nicotine on endogenous GABA efflux from guinea-pig cortical slices. 138
Role of LRRK2 in the regulation of dopamine receptor trafficking 137
Blockade of nociceptin/orphanin FQ receptor signaling in rat substantia nigra pars reticulata stimulates nigrostriatal dopaminergic transmission and motor behavior 136
The nociceptin/orphanin FQ receptor antagonist J-113397 and L-DOPA additively attenuate experimental parkinsonism through overinhibition of the nigrothalamic pathway 135
Pharmacological profile of nociceptin/orphanin FQ receptors regulating 5-hydroxytryptamine release in the mouse neocortex 135
In vivo evidence for a differential contribution of striatal and nigral D1 and D2 receptors to L-DOPA induced dyskinesia and the accompanying surge of nigral amino acid levels 134
Glutamate antagonists prevent morphine withdrawal in mice and guinea pigs 134
Progressive Motor Cortex Functional Reorganization Following 6-Hydroxydopamine Lesioning in Rats 133
Dopamine-nociceptin/orphanin FQ interactions in the substantia nigra reticulata of hemiparkinsonian rats: Involvement of D2/D3 receptors and impact on nigro-thalamic neurons and motor activity 131
Nociceptin/Orphanin FQ Receptor Agonists Attenuate L-DOPA-Induced Dyskinesias 131
Nocistatin inhibits 5-hydroxytryptamine release in the mouse neocortex via presynaptic G i/o protein linked pathways 130
Genetic and pharmacological evidence that G2019S LRRK2 confers a hyperkinetic phenotype, resistant to motor decline associated with aging 129
Genetic deletion of Rhes or pharmacological blockade of mTORC1 prevent striato-nigral neurons activation in levodopa-induced dyskinesia 127
Protein Kinase C β: a New Target Therapy to Prevent the Long-Term Atypical Antipsychotics-Induced Weight-Gain. 127
NR2B subunit blockade does not affect motor symptoms induced by 3-nitropropionic acid 127
NMDA and non-NMDA ionotropic glutamate receptors modulate striatal acetylcholine release via pre- and postsynaptic mechanisms 126
Striatal glutamate release evoked in vivo by NMDA is dependent upon ongoing neuronal activity in the substantia nigra, endogenous striatal substance P and dopamine 125
Chronic and acute LRRK2 silencing has no long-term behavioral effects, whereas wild-type and mutant LRRK2 overexpression induce motor and cognitive deficits and altered regulation of dopamine release 125
Differential responsiveness of rat striatal nerve endings to the mitochondrial toxin 3-nitropropionic acid: implications for Huntington’s disease 125
Antagonism of metabotropic glutamate receptor type 5 attenuates L-DOPA-induced dyskinesia and its molecular and neurochemical correlates in a rat model of Parkinson's disease 124
Blockade of nociceptin/orphanin FQ transmission attenuates symptoms and neurodegeneration associated with Parkinson's disease 124
Striatal Dopamine-NMDA receptor interactions in the modulation of glutamate release in the substantia nigra pars reticulata in vivo: opposite role for D1 and D2 receptors 122
Effect of acute and subchronic nicotine treatment on cortical efflux of [3H]-D-aspartate and endogenous GABA in freely moving guinea-pigs. 122
Antagonisti dei recettori NOP e loro usi terapeutici 121
Olanzapine, but not clozapine, increases glutamate release in the prefrontal cortex of freely moving mice by inhibiting D-aspartate oxidase activity 120
Pharmacological profiles of presynaptic nociceptin/orphanin FQ receptors modulating 5-hydroxytryptamine and noradrenaline release in the rat neocortex. 119
Mechanisms underlying the impairment of hippocampal long-term potentiation and memory in experimental Parkinson's disease 119
Differential effect of NR2A and NR2B subunit selective NMDA receptor antagonists on striato-pallidal neurons: relationship to motor response in the 6-hydroxydopamine model of parkinsonism 118
Functional neuroanatomy of the nigrostriatal and striatonigral pathways as studied with dual probe microdialysis in the awake rat - I. Effects of perfusion with tetrodotoxin and low-calcium medium 118
Effect of (-)nicotine on GABA efflux from guinea pig cerebral cortex slices. 118
Plasticity of glutamatergic control of striatal acetylcholine release in experimental parkinsonism: opposite changes at group-II metabotropic and NMDA receptors 118
Lipid nanocarriers containing a Levodopa prodrug with potential antiparkinsonian activity 118
Inhibitory effect of NMDA receptor activation on quisqualate-stimulated phosphatidylinositol turnover in the human cerebral cortex 116
Changes of glutamatergic control of striatal acetylcholine release in experimental parkinsonism 116
Nociceptin/Orphanin FQ Inhibits the Survival and Axon Growth of Midbrain Dopaminergic Neurons Through a p38-MAPK Dependent Mechanism 116
Loss of the preferential control over the striato-nigral direct pathway by striatal NMDA receptors in a rat model of Parkinson's disease 116
Nanoparticulate lipid dispersions for bromocriptine delivery: characterization and in vivo study 115
Pharmacological and genetic evidence for pre- and postsynaptic D2 receptor involvement in motor responses to nociceptin/orphanin FQ receptor ligands 114
Excitatory amino acids (EAAs) stimulate phosphatidylinositol turnover in adult rat striatal slices: interaction between NMDA and EAA metabotropic receptors. 113
null 113
Pharmacological characterization of the nociceptin/orphanin FQ receptor antagonist SB-612111 [(-)-cis-1-methyl-7-[[4-(2,6-dichlorophenyl)piperidin-1-yl] methyl]-6,7,8,9-tetrahydro-5H-benzocyclohepten-5-ol]: In vitro studies 113
Increased responsivity of glutamate release from the substantia nigra pars reticulata to striatal NMDA receptor blockade in a model of Parkinson's disease. A dual probe microdialysis study in hemiparkinsonian rats 111
Presynaptic group I and II metabotropic glutamate receptors oppositely modulate striatal acetylcholine release 110
null 108
Dopamine D2 receptor-mediated neuroprotection in a G2019S Lrrk2 genetic model of Parkinson's disease 107
Selectivity and Anti-Parkinsons Potential of Thiadiazolidinone RGS4 Inhibitors 107
Evidence for a protective action of the vigilance promoting drug modafinil on the MPTP-induced degeneration of the nigrostriatal dopamine neurons in the black mouse: an immunocytochemical and biochemical analysis 106
Differential role of striatal and nigral D1receptors in the expression of L-DOPA induced dyskinesia and its neurochemical correlates 104
Nociceptin/orphanin FQ receptors modulate glutamate extracellular levels in the substantia nigra pars reticulata: A microdialysis study in the awake freely moving rat. 103
Nociceptin/orphanin FQ and neurotransmitter release in the central nervous system 103
Parkinson's disease: no NOP, new hope 103
Leucine-rich repeat kinase 2 controls protein kinase A activation state through phosphodiesterase 4 103
Autophagy and LRRK2 in the Aging Brain 102
Nociceptin/orphanin FQ receptors modulate locomotion and motor cortex excitability in adult Rats 101
Alpha-2 adrenoreceptor-mediated decrease in gamma-aminobutyric acid outflow in cortical slices and synaptosomes during morphine tolerance. 101
Metabotropic glutamate 2 receptors modulate synaptic inputs and calcium signals in striatal cholinergic interneurons 101
Evidence for a striatal NMDA receptor modulation of nigral glutamate release. A dual probe microdialysis study in the awake freely moving rat 98
Leucine-rich repeat kinase 2 (LRRK2) inhibitors differentially modulate glutamate release and Serine935 LRRK2 phosphorylation in striatal and cerebrocortical synaptosomes 97
The selective D3 receptor antagonist, S33084, improves parkinsonian-like motor dysfunction but does not affect L-DOPA-induced dyskinesia in 6-hydroxydopamine hemi-lesioned rats 96
Blockade of nociceptin/orphanin FQ transmission in rat substantia nigra reverses haloperidol-induced akinesia and normalizes nigral glutamate release 96
L-dopa-induced dyskinesia: beyond an excessive dopamine tone in the striatum 95
Nanostructured lipid carriers as delivery systems for parkinson’s therapy 94
null 94
Modulation of 5-hydroxytryptamine efflux from rat cortical synaptosomes by opioids and nociceptin 93
NOP receptor ligands and Parkinson’s disease 93
G2019S LRRK2 mutation facilitates α-synuclein neuropathology in aged mice 93
Synthesis and structure activity relationships of delthorphine analogues 92
null 92
null 92
null 91
null 89
null 88
Stimulation of Delta Opioid Receptor and Blockade of Nociceptin/Orphanin FQ Receptor Synergistically Attenuate Parkinsonism 88
Direct and indirect inhibition by nociceptin/orphanin FQ on noradrenaline release from rodent cerebral cortex in vitro 88
Agonisti dei recettori NOP per il trattamento delle discinesie da levodopa; 87
null 87
null 87
L-glutamate and gamma-aminobutyric acid efflux from rat cerebrocortical synaptosomes: Modulation by kappa- and mu- but not delta- and opioid receptor like-1 receptors 85
null 84
Dopamine D2 receptor activation potently inhibits striatal glutamatergic transmission in a G2019S LRRK2 genetic model of Parkinson's disease 84
Nociceptin/orphanin FQ receptor antagonists riverse akinesia in rat parkinsonian models 82
null 82
Physiopathological aspects of NMDA transmission in the basal ganglia. In vitro and in vivo release studies 80
Gene Co-expression Analysis Identifies Histone Deacetylase 5 and 9 Expression in Midbrain Dopamine Neurons and as Regulators of Neurite Growth via Bone Morphogenetic Protein Signaling 79
PRIN 2008. ente finanziatore MIUR. titolo"Nuovi approcci terapeutici per le discinesie indotte dal trattamento con L-DOPA in un modello sperimentale di Parkinson: ruolo delle subunità del recettore NMDA e della via molecolare Ras-ERK" 78
Totale 11.834
Salva come PNG Salva come JPEG
Categoria #
all - tutte 79.793
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 1.660
Totale 81.453
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/2020553 0 0 0 0 0 0 0 0 0 282 206 65
2020/20212.004 165 170 94 225 111 166 104 237 67 262 264 139
2021/20221.562 53 169 130 70 81 95 98 87 55 117 153 454
2022/20231.619 170 132 75 181 263 218 72 124 224 4 101 55
2023/2024803 84 103 39 23 76 135 34 63 24 19 9 194
2024/20252.549 74 88 310 82 402 505 146 204 569 169 0 0
Totale 15.093